NCT07730216

Brief Summary

Total knee arthroplasty (TKA) is associated with substantial postoperative pain and opioid requirements, making effective multimodal analgesia essential for early mobilization, functional recovery, and reduction of opioid-related adverse events \[1,2\]. Adductor canal block (ACB) has become a key component of enhanced recovery after surgery (ERAS) protocols because it provides effective anterior knee analgesia while largely preserving quadriceps muscle strength \[2-4\]. However, analgesic efficacy after ACB remains variable, and some patients require rescue opioid analgesia despite technically successful block placement \[5\]. Although ultrasound guidance improves block accuracy, factors such as tissue depth, anatomical variations, saphenous nerve visibility, and injectate spread pattern may influence clinical outcomes \[6,7\]. Prospective evidence regarding the predictive value of these ultrasound-derived parameters for ACB analgesic failure remains limited. Therefore, this study aims to evaluate whether preoperative ultrasound-derived tissue and target parameters-including skin-to-target depth, subcutaneous fat thickness, muscle thickness, saphenous nerve visibility, and injectate spread pattern-can predict ACB analgesic failure and early postoperative analgesic outcomes following TKA.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
623

participants targeted

Target at P75+ for all trials

Timeline
11mo left

Started Jul 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Jul 2026Jul 2027

First Submitted

Initial submission to the registry

July 13, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

July 13, 2026

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 28, 2026

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 13, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 13, 2027

Last Updated

July 28, 2026

Status Verified

July 1, 2026

Enrollment Period

1 year

First QC Date

July 13, 2026

Last Update Submit

July 23, 2026

Conditions

Keywords

Adductor Canal BlockTotal Knee ArthroplastyUltrasoundPostoperative Analgesia

Outcome Measures

Primary Outcomes (1)

  • ACB Failure

    ACB analgesic failure will be defined as the requirement for rescue analgesia during the first 24 hours after block administration, with intravenous tramadol (1 mg/kg) administered to patients with an NRS pain score ≥4.

    0-24 hours

Secondary Outcomes (2)

  • Secondary outcome

    0-24 hour

  • Tramadol Consumption

    0-24 Hours

Interventions

The adductor canal block (ACB) will be performed in the post-anesthesia care unit (PACU) after regression of spinal anesthesia.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia

You may qualify if:

  • Age ≥18 years
  • Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-III

You may not qualify if:

  • Daily opioid use or chronic pain syndrome
  • Diabetic or other clinically diagnosed peripheral neuropathy
  • Coagulopathy
  • Infection at the injection site
  • Known allergy or hypersensitivity to local anesthetics
  • Revision total knee arthroplasty
  • Conversion from spinal anesthesia to general anesthesia during surgery
  • General anesthesia as the planned anesthetic technique

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Konya City Hospital

Konya, Konya, 42090, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pain

Interventions

Single Person

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Marital StatusFamily CharacteristicsDemographyPopulation CharacteristicsSocioeconomic Factors

Central Study Contacts

Ömer Keklicek, Principal Investigator

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

July 13, 2026

First Posted

July 28, 2026

Study Start

July 13, 2026

Primary Completion (Estimated)

July 13, 2027

Study Completion (Estimated)

July 13, 2027

Last Updated

July 28, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations